Moderna receives EC marketing authorization for mCOMBRIAX

Moderna (MRNA) announced that the European Commission has granted marketing authorization for mCOMBRIAX, the Company’s mRNA combination vaccine for active immunization for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older. This marketing authorization follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use and is valid in all 27 European Union member states, as well as Iceland, Liechtenstein and Norway. mCOMBRIAX is Moderna’s fourth authorized product, further strengthening the Company’s respiratory portfolio and commitment to the European Union.